The response of elderly veterans to daily vitamin D3 supplementation of 2,000 IU

A pilot efficacy study

Evan Paul Cherniack, Hermes J Florez, Bruce W. Hollis, Bernard A. Roos, Bruce R. Troen, Silvina Levis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To determine the prevalence of hypovitaminosis D (serum 25-hydroxyvitamin D<32 ng/mL; HVD) in a population of elderly veterans and conduct a preliminary assessment of the efficacy of supplementation with cholecalciferol in correcting HVD. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Geriatric clinic at the Bruce W. Carter Veterans Affairs Medical Center, Miami, Florida. Participants: Veterans aged 70 and older. Intervention: Oral cholecalciferol 2,000 IU daily or placebo for 6 months. Measurements: Serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and 24-hour urinary calcium. Results: Of the 34 participants who completed the study, 62% had HVD at baseline. In the treatment group, mean serum 25-hydroxyvitamin D level rose from 28.4±7.9 ng/mL at baseline to 42.7±10.5 ng/mL at the end of the trial, but levels remained less than 32 ng/mL in three of 17 (18%) of the participants. In the placebo group, the baseline level of 27.7±8.3 ng/mL remained unchanged (28.8±8.7 ng/mL). Supplementation did not alter serum or urinary calcium levels and did not result in any adverse events. Conclusion: These initial observations suggest that, in older veterans, cholecalciferol 2,000 IU daily for 6 months is generally safe and corrects HVD in most but not all individuals.

Original languageEnglish
Pages (from-to)286-290
Number of pages5
JournalJournal of the American Geriatrics Society
Volume59
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Cholecalciferol
Veterans
Placebos
Calcium
Serum
Controlled Clinical Trials
Parathyroid Hormone
Geriatrics
Population
25-hydroxyvitamin D
Therapeutics

Keywords

  • elderly
  • veterans
  • vitamin D

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

The response of elderly veterans to daily vitamin D3 supplementation of 2,000 IU : A pilot efficacy study. / Cherniack, Evan Paul; Florez, Hermes J; Hollis, Bruce W.; Roos, Bernard A.; Troen, Bruce R.; Levis, Silvina.

In: Journal of the American Geriatrics Society, Vol. 59, No. 2, 01.02.2011, p. 286-290.

Research output: Contribution to journalArticle

@article{493b61a77e494e5e91456f6942f6765b,
title = "The response of elderly veterans to daily vitamin D3 supplementation of 2,000 IU: A pilot efficacy study",
abstract = "Objective: To determine the prevalence of hypovitaminosis D (serum 25-hydroxyvitamin D<32 ng/mL; HVD) in a population of elderly veterans and conduct a preliminary assessment of the efficacy of supplementation with cholecalciferol in correcting HVD. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Geriatric clinic at the Bruce W. Carter Veterans Affairs Medical Center, Miami, Florida. Participants: Veterans aged 70 and older. Intervention: Oral cholecalciferol 2,000 IU daily or placebo for 6 months. Measurements: Serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and 24-hour urinary calcium. Results: Of the 34 participants who completed the study, 62{\%} had HVD at baseline. In the treatment group, mean serum 25-hydroxyvitamin D level rose from 28.4±7.9 ng/mL at baseline to 42.7±10.5 ng/mL at the end of the trial, but levels remained less than 32 ng/mL in three of 17 (18{\%}) of the participants. In the placebo group, the baseline level of 27.7±8.3 ng/mL remained unchanged (28.8±8.7 ng/mL). Supplementation did not alter serum or urinary calcium levels and did not result in any adverse events. Conclusion: These initial observations suggest that, in older veterans, cholecalciferol 2,000 IU daily for 6 months is generally safe and corrects HVD in most but not all individuals.",
keywords = "elderly, veterans, vitamin D",
author = "Cherniack, {Evan Paul} and Florez, {Hermes J} and Hollis, {Bruce W.} and Roos, {Bernard A.} and Troen, {Bruce R.} and Silvina Levis",
year = "2011",
month = "2",
day = "1",
doi = "10.1111/j.1532-5415.2010.03242.x",
language = "English",
volume = "59",
pages = "286--290",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The response of elderly veterans to daily vitamin D3 supplementation of 2,000 IU

T2 - A pilot efficacy study

AU - Cherniack, Evan Paul

AU - Florez, Hermes J

AU - Hollis, Bruce W.

AU - Roos, Bernard A.

AU - Troen, Bruce R.

AU - Levis, Silvina

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Objective: To determine the prevalence of hypovitaminosis D (serum 25-hydroxyvitamin D<32 ng/mL; HVD) in a population of elderly veterans and conduct a preliminary assessment of the efficacy of supplementation with cholecalciferol in correcting HVD. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Geriatric clinic at the Bruce W. Carter Veterans Affairs Medical Center, Miami, Florida. Participants: Veterans aged 70 and older. Intervention: Oral cholecalciferol 2,000 IU daily or placebo for 6 months. Measurements: Serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and 24-hour urinary calcium. Results: Of the 34 participants who completed the study, 62% had HVD at baseline. In the treatment group, mean serum 25-hydroxyvitamin D level rose from 28.4±7.9 ng/mL at baseline to 42.7±10.5 ng/mL at the end of the trial, but levels remained less than 32 ng/mL in three of 17 (18%) of the participants. In the placebo group, the baseline level of 27.7±8.3 ng/mL remained unchanged (28.8±8.7 ng/mL). Supplementation did not alter serum or urinary calcium levels and did not result in any adverse events. Conclusion: These initial observations suggest that, in older veterans, cholecalciferol 2,000 IU daily for 6 months is generally safe and corrects HVD in most but not all individuals.

AB - Objective: To determine the prevalence of hypovitaminosis D (serum 25-hydroxyvitamin D<32 ng/mL; HVD) in a population of elderly veterans and conduct a preliminary assessment of the efficacy of supplementation with cholecalciferol in correcting HVD. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Geriatric clinic at the Bruce W. Carter Veterans Affairs Medical Center, Miami, Florida. Participants: Veterans aged 70 and older. Intervention: Oral cholecalciferol 2,000 IU daily or placebo for 6 months. Measurements: Serum calcium, 25-hydroxyvitamin D, parathyroid hormone, and 24-hour urinary calcium. Results: Of the 34 participants who completed the study, 62% had HVD at baseline. In the treatment group, mean serum 25-hydroxyvitamin D level rose from 28.4±7.9 ng/mL at baseline to 42.7±10.5 ng/mL at the end of the trial, but levels remained less than 32 ng/mL in three of 17 (18%) of the participants. In the placebo group, the baseline level of 27.7±8.3 ng/mL remained unchanged (28.8±8.7 ng/mL). Supplementation did not alter serum or urinary calcium levels and did not result in any adverse events. Conclusion: These initial observations suggest that, in older veterans, cholecalciferol 2,000 IU daily for 6 months is generally safe and corrects HVD in most but not all individuals.

KW - elderly

KW - veterans

KW - vitamin D

UR - http://www.scopus.com/inward/record.url?scp=79951631670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951631670&partnerID=8YFLogxK

U2 - 10.1111/j.1532-5415.2010.03242.x

DO - 10.1111/j.1532-5415.2010.03242.x

M3 - Article

VL - 59

SP - 286

EP - 290

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 2

ER -